After a lull in the IPO market since the SBI Card issue, Rossari Biotech is kick-startingthe IPO season with its Rs 496 crore fresh issue and offer-for- sale (OFS). The company already garnered Rs 149 crore through its anchor book on July 10 and has been subscribed 8 percent so far on July 13, day one of bidding. … [Read more...] about Ideas for Profit | Rossari Biotech IPO opens for subscription today; should you subscribe?
As far as Yes Bank’s FPO is concerned it is a high-risk high reward punt for equity investors who have a high-risk appetite as this investment will require patience. Recovery in Yes Bank could take a while with SBI’s support and in the process, there can be many ups and downs. … [Read more...] about Rossari Biotech IPO, Bharat Bond ETF & Yes Bank FPO: Where should investors put their money?
In its latest update on the drug, Gilead said on July 10 that an analysis showed remdesivir helped reduce the risk of death in severely ill COVID-19 patients but cautioned that rigorous clinical trials were needed to confirm the benefit. … [Read more...] about One in three South Korean COVID-19 patients improved with remdesivir
"The new capacity expansion at Dahej (1,32,500 MTPA) with Rs 90 crore capex should strengthen its portfolio in the high-growth HPPC segment to serve its wide customer base. Customised product offering, fungible capacities and rapid finished product conversion rate remain the key differentiators for the company," said Emkay. It, too, favoured subscribing the issue. … [Read more...] about Analysts say subscribe to Rossari Biotech IPO despite high valuation, here is why
"A robust management and sound corporate governance policy will drive growth going forward and this is already visible in its current return ratios (RoCE 25 percent and RoNW of 32 percent in FY20). Since its P/E is slightly overvalued at 31x compared to average P/E of 27x, short term investors can subscribe only for listing gains. However, for long term investors can hold on to this stock as it is still a fair deal because the handsome growth and strong book with a mere 0.3 Debt/equity ratio and sufficient cash still justify the valuation," Nirali said. … [Read more...] about Rossari Biotech IPO opens today, subscribed 34% so far on Day 1